Dizal Pharmaceutical(SH:688192)2022-04-27 16:00Financial Performance - The company reported a total revenue of 0 RMB for Q1 2022, indicating no commercial sales as all products are still in the research and development phase[3]. - The net profit attributable to shareholders was -181,726,770.92 RMB, with a net profit excluding non-recurring gains and losses of -193,822,904.38 RMB[4]. - The basic and diluted earnings per share for the period were both -0.45 RMB[4]. - The weighted average return on net assets was -7.65% for the reporting period[4]. - Net loss for Q1 2022 was CNY 181.73 million, compared to a net loss of CNY 135.45 million in Q1 2021, indicating a worsening of approximately 34.2%[19]. - Basic and diluted earnings per share for Q1 2022 were both CNY -0.45, compared to CNY -0.38 in Q1 2021, reflecting a decrease of approximately 18.4%[21]. Cash Flow and Investments - The net cash flow from operating activities was -172,890,065.46 RMB, reflecting ongoing investment in R&D and operational costs[4]. - Cash flow from operating activities increased to CNY 7.57 million in Q1 2022 from CNY 6.92 million in Q1 2021, an increase of about 9.4%[22]. - The net cash flow from investment activities was 63,199,017.79, a decrease from 64,549,459.07 in the previous year[24]. - The net cash flow from financing activities was -18,346,569.54, compared to -4,302,261.95 in the previous year, indicating a higher outflow related to financing[24]. - The net increase in cash and cash equivalents was -128,698,761.06, compared to -65,202,028.74 in the previous year, showing a worsening liquidity position[25]. - The ending balance of cash and cash equivalents was 235,264,870.21, down from 443,545,066.76 in the previous year[25]. - The company reported a significant increase in cash received from investment recoveries, totaling 2,200,000,000.00, compared to 203,000,000.00 in the previous year[24]. - Cash paid for purchasing fixed assets and other long-term assets was 3,571,640.00, compared to 817,699.12 in the previous year, indicating increased capital expenditures[24]. Research and Development - R&D expenses totaled 168,406,675.29 RMB, representing a 40.92% increase compared to the previous year[4]. - The company is focusing on expanding its product pipeline, particularly with DZD9008 and DZD4205, which are in critical registration clinical stages[8]. - The company has five products in global clinical stages, with two leading products recognized as breakthrough therapies by regulatory authorities[12]. Assets and Liabilities - Total assets decreased by 6.62% from the end of the previous year, amounting to 2,564,066,698.62 RMB[4]. - Current assets totaled RMB 1,932,538,262.14, down from RMB 2,112,337,442.79, indicating a decrease of about 8.5%[14]. - Cash and cash equivalents were RMB 235,539,870.21, compared to RMB 364,238,631.27 in the previous year, reflecting a decline of approximately 35.4%[13]. - The company’s investment in fixed assets was RMB 11,789,624.83, down from RMB 12,999,121.87, a decrease of about 9.3%[14]. - The company’s long-term equity investments remained unchanged at RMB 0, indicating no new investments in this category[14]. - Total liabilities decreased from CNY 282.91 billion in Q1 2021 to CNY 278.01 billion in Q1 2022, a reduction of approximately 1.03%[15]. - The company's total equity attributable to shareholders decreased from CNY 2.46 billion in Q1 2021 to CNY 2.29 billion in Q1 2022, a decline of about 7.14%[16]. Shareholder Structure - The company’s shareholder structure includes significant stakes held by related parties, with ZYTZ and its concerted actions holding a combined 15.49%[11].